Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress

Join us for an exciting webinar which will explore recent breakthroughs and ongoing challenges in the ALS landscape, including the biological drivers of disease and how advances in drug development are improving the patient experience, while underscoring where significant gaps remain. The discussion will highlight Coya’s novel immunotherapy approach for treating ALS, including the scientific rationale behind its combination therapy COYA 302 and will feature an overview of the Company’s ALSTARS Phase 2 clinical trial, including its design and enrollment information.